Comparison of Lupus Nephritis Onset Before and After Age 50: Effect on Presentation and Outcomes in an Inception Cohort.

J Rheumatol

L.P. Whittall Garcia, MD, MSc, University of Toronto Lupus Clinic, Division of Rheumatology, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada.

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: Renal involvement in systemic lupus erythematosus (SLE) most commonly occurs in women in the reproductive age group; however, it may theoretically start at any age. In this study, we aimed to explore the effect of lupus nephritis (LN) stratified by age of onset, with a cutoff at 50 years, on clinical presentation and disease outcomes.

Methods: We included 246 inception cohort patients who developed LN during follow-up. We classified patients based on the age of LN onset into group 1 (< 50 years; 205 patients) and group 2 (≥ 50 years, late-onset LN; 41 patients). Outcomes included complete proteinuria recovery (CPR) at 1 year, an adverse composite outcome (end-stage renal disease, a sustained ≥ 40% decline in estimated glomerular filtration rate [eGFR], or death), subsequent LN flares, and any increase in nonrenal Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). The association with outcomes was studied using the Cox proportional hazards model.

Results: At baseline, the median age was 31.4 (IQR 25.2-38.5) years for group 1 and 58.4 (IQR 53.9-64.5) years for group 2 ( < 0.01). Group 2 (late-onset LN) patients had a higher median creatinine level ( = 0.03), lower median eGFR ( < 0.01) and proteinuria levels ( = 0.01), and a lower median SLE Disease Activity Index 2000 (SLEDAI-2K) score ( = 0.04). In the Cox models, there were no significant differences between the 2 groups in terms of achieving CPR or developing the adverse composite outcome. However, late-onset LN was associated with higher odds of any increase in nonrenal SDI and showed a trend for fewer subsequent flares.

Conclusion: Late-onset LN is not associated with significant differences in short- or long-term renal outcomes.

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.2024-1278DOI Listing

Publication Analysis

Top Keywords

lupus nephritis
8
inception cohort
8
systemic lupus
8
age onset
8
late-onset patients
8
adverse composite
8
composite outcome
8
increase nonrenal
8
years group
8
lower median
8

Similar Publications

Case Report: Sequential treatment with rituximab and belimumab in a pediatric patient of type 1 diabetes mellitus complicated with systemic lupus erythematosus.

Front Pediatr

August 2025

Department of Rheumatology and Immunology, Tianjin Children's Hospital (Children's Hospital, Tianjin University), Tianjin Key Laboratory of Birth Defects for Prevention and Treatment, Tianjin, China.

Type 1 diabetes mellitus (T1DM) and systemic lupus erythematosus (SLE) are both autoimmune diseases influenced by multiple genetic and environmental factors, but rarely coexist. This case describes a 13-year-old girl with early onset of T1DM who was diagnosed with SLE 12 years later, highlighting diagnostic and therapeutic challenges, particularly in distinguishing kidney involvement and management without exacerbating hyperglycemia. The patient presented with edema of the eyelids and lower limbs.

View Article and Find Full Text PDF

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by complex disturbances in both innate and adaptive immune responses, often leading to multi-organ involvement. One of the key features of SLE pathogenesis is endothelial dysfunction, which contributes to immune cell infiltration and vascular inflammation. In this context, adhesion molecules such as platelet endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) may reflect the degree of endothelial activation.

View Article and Find Full Text PDF

The present investigation elucidates the therapeutic potential of glycyrrhizin, the predominant triterpene saponin isolated from (licorice), in the management of systemic lupus erythematosus (SLE), an autoimmune disorder characterized by multisystemic involvement and therapeutic recalcitrance. Comprehensive interrogation of multiple disease-specific databases facilitated the identification of crucial SLE-associated molecular targets and hub genes, with MAPK1, MAPK3, TP53, JUN, and JAK2 demonstrating the highest degree of network centrality. Subsequent molecular docking simulations and binding affinity assessments revealed compounds with exceptional complementarity to these pivotal molecular targets, establishing as a pharmacologically promising botanical source and glycyrrhizin as its principal bioactive constituent meriting comprehensive mechanistic investigation.

View Article and Find Full Text PDF

 is a protozoan parasite that typically causes self-limited diarrhea in healthy individuals but can result in prolonged, severe illness in those who are immunocompromised. While this infection is well recognized in HIV-positive patients, it is less frequently reported in individuals with lupus nephritis on immunosuppressive therapy. We report the case of a 27-year-old man with biopsy-confirmed class IV lupus nephritis who was receiving cyclophosphamide and corticosteroids.

View Article and Find Full Text PDF

Introduction: Anti-neutrophil cytoplasmic antibodies (ANCAs) have been reported in systemic lupus erythematosus (SLE). Their clinical significance remains unclear especially in the African populations. This study aimed to assess the prevalence, antigenic targets, and clinical correlations of ANCAs in SLE patients in a Tunisian (North African) cohort.

View Article and Find Full Text PDF